leisure time -WSS

leisure time

author：focus 2025-08-26 23:48:38 - browse：9784

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Hospitals struggle to profit from CAR

WSS

Driven by the pandemic, applicants flood public health schools

Tesla recalling nearly 16,000 of its 2021

Liquid biopsy for lung cancer is launched by Delfi

AI can decode, harness the power of the humane immune system

Affordable Connectivity Program vital to health care, experts say

Stanford president's case begs question: Who takes blame?

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Continuity nursing helped my family in our darkest PICU moments

Driven by the pandemic, applicants flood public health schools

Heart attack and stroke risk calculators need revising

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Drug repurposing or repositioning? The language matters

Awakening the world to the whoosh: A patient's crusade

Psychedelics group wrestles with new pharma identity

Mass General totes up its waste in a move to tackle climate change

Virginia high school admissions case could be legal follow

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

leisure time

Bristol 'take

Affordable Connectivity Program vital to health care, experts say

Awakening the world to the whoosh: A patient's crusade

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Vir antibody drug aimed at influenza A fails in clinical trial

focus

Wikipedia

leisure time

hotspot